- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02315560
Foot Neuromodulation for Nocturnal Enuresis
Foot Neuromodulation for Nocturnal Enuresis in Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh og UPMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children ages 5 to 16 years old without any specific neurological disorder or urinary tract infection, clinically diagnosed as having nocturnal enuresis AT LEAST 4 episodes per month by history
- Currently having no daytime overactive bladder symptoms, i.e. urinary frequency, urgency, or daytime incontinence
- Having been assessed for and treated if applicable for behavioral etiologies of nocturnal enuresis - consuming excess fluids or specific bladder irritants
- Having been assessed for and treated if applicable for constipation
Exclusion Criteria:
- Children with known neurological disorders which may be contributing to nocturnal enuresis episodes
- Children found through history to have significant behavioral causes of nocturnal enuresis including consumption of excessive fluids or known bladder irritants
- Children with chronic constipation who are non-compliant with previous pharmacologic efforts to treat.
- Children who are not adequately potty trained
- Children with significant daytime symptoms of overactive bladder including frequency, urgency, and daytime incontinence
5. Children who do not tolerate initial stimulation training session in the urology clinic upon enrollment
6. Children with any implantable medical devices such as a pacemaker will be excluded from the study
Note: Any patient currently taking medication such as an anti-muscarinic or a tricyclic antidepressant for overactive bladder at time of enrollment will be eligible to participate and will be continued on their usual medication and dosage throughout the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Tibial Nerve Stimulation
The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night.
This log is included in the Institutional Review Board application.
Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
|
electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Decrease in Nocturnal Enuresis
Time Frame: 6 weeks
|
To determine if foot stimulation can decrease nocturnal enuresis in children as measured by daily night-time voiding log.
The outcome is the number of participants that had a clinical response with improvement of at least 1 wet night reduction during the 6-week stimulation period.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life Questionnaire Scores
Time Frame: 6 weeks
|
The NLUTD/DES questionnaire (Neurogenic Lower Urinary Tract Dysfunction/Dysfunctional Elimination Syndrome) has been validated and is reliable for assessing lower urinary tract and bowel dysfunction.
The questionnaire is scored using a 5-point Likert scale.
The questionnaire consists of a total of 14 questions, each question asking about a symptom.
Question #7 specifically addresses nocturnal enuresis.
A score of 4 indicates severe symptoms, while a score of 0 indicates none.
The maximum score is 52, indicating the most severe symptoms, while the minimum score of zero indicates zero symptoms.
Scores of 11 or greater indicate bladder or bowel dysfunction.
|
6 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO14080250
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bedwetting
-
Rajeev ChaudhrySociety of Urodynamics and Female Urology The Coulter FoundationCompleted
-
Heidi StephanyCMI's Early-Stage Medical Technology Research and Development 2015 PILOT...Withdrawn
-
Northwell HealthAlbany Medical College; Feinstein Institute for Medical ResearchCompletedTranscutaneous Electric Nerve Stimulation (TENS) for the Treatment of Nocturnal Enuresis in ChildrenNocturnal Enuresis | BedwettingUnited States
-
Albany Medical CollegeRecruitingNocturnal Enuresis | BedwettingUnited States
-
Yale UniversityFood and Drug Administration (FDA); Southwest pediatric Device ConsortiumTerminatedUrinary Incontinence | Nocturnal Enuresis | BedwettingUnited States
Clinical Trials on TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS
-
Rajeev ChaudhryWithdrawn
-
Sheba Medical CenterUnknown
-
University Hospital, ToulouseMinistry of Health, FranceTerminatedPeripheral Artery DiseaseFrance
-
Karolinska University HospitalActive, not recruitingHip Fractures | Orthopedic Disorder | Post Operative Pain | Arthroplasty, Replacement, Hip | Internal FixationSweden
-
University of California, Los AngelesCompletedDepression | Post-traumatic Stress DisorderUnited States
-
Université de SherbrookeCompleted
-
Institut Cancerologie de l'OuestTerminated
-
Hawra Al-DandanRecruitingOveractive Bladder SyndromeSaudi Arabia
-
University of the Sinos ValleyNot yet recruitingHip Fractures | Femoral Neck Fractures | Intertrochanteric Femur Fracture